Szymon Drygała

Szymon Drygała

Auto-generated profile, based on publicly available information

Szymon Drygała

Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, Bialystok 15-089, Poland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SDSzymon Drygała
Szymon Drygała
Michał RadzikowskiMichał Radzikowski
Michał Radzikowski
MMMateusz Maciejczyk
Mateusz Maciejczyk
The growing burden of metabolic disorders manifested by hypertension, type 2 diabetes mellitus, hyperlipidemia, obesity and non-alcoholic fatty liver disease presents a significant global health challenge by contributing to cardiovascular diseases and high mortality rates. Β-blockers are among the most widely used drugs in the treatment of hypertension and acute cardiovascular events. In addition to blocking the receptor sites for catecholamines, third-generation β-blockers with associated vasodilating properties, such as carvedilol and nebivolol, provide a broad spectrum of metabolic effects, including anti-inflammatory and antioxidant properties and a favorable impact on glucose and lipid metabolism. This review aims to report the impact of β-blockers on metabolic modulation based on available literature data. We present an overview of β-blockers and their pleiotropic properties, discuss mechanisms by which these drugs affect cellular metabolism and outline the future perspectives. The influence of β-blockers on glucose metabolism, insulin sensitivity, inflammation and oxidative stress is complex and varies depending on the specific β-blocker used, patient population and underlying health conditions. Recent evidence particularly highlights the potential role of vasodilatory and nitric oxide-mediated properties of nebivolol and carvedilol in improving glycemic control, insulin sensitivity, and lipid metabolism and mitigating oxidative stress and inflammation. It suggests that these drugs may be potential therapeutic options for patients with metabolic disorders, extending beyond their primary role in cardiovascular management.

1 January 2023 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
Piotr EderPiotr Eder
Piotr Eder
MKMaria Kłopocka
Maria Kłopocka
HCHalina Cichoz-Lach
Halina Cichoz-Lach
RTRenata Talar-Wojnarowska
Renata Talar-Wojnarowska
MKMaria Kopertowska-Majchrzak
Maria Kopertowska-Majchrzak
EZEdyta Zagórowicz
Edyta Zagórowicz
Background: Vedolizumab is a gut-selective anti-lymphocyte trafficking agent used to treat ulcerative colitis (UC) and Crohn’s disease. Objectives: We aimed to evaluate the effectiveness, safety, and durability of the therapeutic effect of vedolizumab after treatment discontinuation in a real-world cohort of patients with UC treated in Poland. Design: This was a multicenter, prospective study involving patients with moderate to severely active UC from 12 centers in Poland who qualified for reimbursed treatment with vedolizumab between February and November 2019. Methods: The primary endpoints were clinical response (⩾2-point improvement from baseline on partial Mayo score) and clinical remission (partial Mayo score 0–1), including steroid-free remission, at week 54. Other outcomes included response durability at 26 weeks after treatment discontinuation, identification of predictors of response and remission, and safety assessment. Results: In all, 100 patients with UC were enrolled (55 biologic naïve and 45 biologic exposed). At baseline, 68% of patients were on corticosteroids and 45% on immunomodulators. Clinical response was observed in 62% of patients, clinical remission in 50%, and steroid-free remission in 42.6% at week 54. Within 26 weeks after treatment discontinuation, 37% of patients who maintained response by week 54 relapsed. The decreased number of liquid stools and rectal bleeding and endoscopic response at week 14 were predictive factors for response at week 54. Time from diagnosis ranging 2–5 years, decreased stool frequency, and non-concomitant use of corticosteroids at baseline and at week 14 were predictive factors for remission at week 54. Partial Mayo score < 3 with no subscale score > 1 at week 54 was a predictive factor for durable response after treatment discontinuation. The rate of serious adverse events related to treatment was 3.63 per 100 patient-years. Conclusion: Vedolizumab is effective and safe in UC treatment in Polish patients. However, the relapse rate after the treatment cessation was high. Registration: ENCePP (EUPAS34119).

21 December 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SDSzymon Drygala
Szymon Drygala
ERElzbieta Rdzanek
Elzbieta Rdzanek
GPGrzegorz Porebski
Grzegorz Porebski
PDPawel Dubiela
Pawel Dubiela
Frequent mislabelled causal relationship between drug hypersensitivity reactions and culprit drugs reinforces the need for an accurate diagnosis. The systematic reviews and meta-analyses of in vitro assays published so far focused on immediate reactions and the most severe delayed reactions, while the most frequent drug-induced delayed reactionsnonsevere exanthemashave been underestimated. We aim to fill this gap. A systematic review of studies on in vitro assays used in the diagnosis of nonsevere drug-induced delayed reactions was conducted following the methodology of Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies Statement. The EMBASE and PubMed databases were searched. We have included 33 studies from which we extracted the data, then performed meta-analysis where possible, or synthesised the evidence narratively. The quality of the analysed studies was assessed with the QUADAS-2 tool. The tests identified the most frequently were lymphocyte transformation test (LTT), ELISpot, and ELISA. In the meta-analysis carried out for LTT in reactions induce by beta-lactams, the pool estimate of sensitivity and specificity amounted to 49.1 (95 CI: 14.0, 85.0) and 94.6 (95 CI: 81.7, 98.6), respectively. The studies showed heterogeneity in study design and laboratory settings, which resulted in a wide range of specificity and sensitivity of testing.

1 January 2024 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
ALAriel Liebert
Ariel Liebert
MKMaria Kłopocka
Maria Kłopocka
AMAgata Michalak
Agata Michalak
HCHalina Cichoz-Lach
Halina Cichoz-Lach
RTRenata Talar-Wojnarowska
Renata Talar-Wojnarowska
SDSzymon Drygała
Szymon Drygała
Background: The Crohn’s Disease (CD) Activity Index (CDAI), Inflammatory Bowel Disease (IBD) Questionnaire (IBDQ), and IBD-Fatigue (IBD-F) scale are useful patient-reported outcome (PRO) tools for assessing the treatment benefits of vedolizumab (VDZ) beyond clinical trial endpoints in patients with CD.Objectives: To assess clinical response, clinical remission, steroid-free remission, changes from baseline for PROs, and safety in a real-world cohort of patients with moderate-to-severe active CD treated with VDZ.Design: POLONEZ II was a multicenter, observational, prospective study across 10 Polish centers from April 2020 to October 2023 for 54 weeks in patients with CD eligible for reimbursed VDZ.Methods: Primary endpoints at week 54 (W54) were clinical response (⩾70-point reduction in CDAI and >25% reduction vs baseline), remission (CDAI score ⩽150), and steroid-free remission. Other outcomes were changes in PROs (CDAI score and health-related quality of life) and safety. Kaplan–Meier survival analyses were performed.Results: Of 98 patients with CD, the mean age was 35.2 years, 57.1% were male, and 72.4% had an ileocolonic disease. At W54 ( n = 98), 63.3% of patients achieved clinical response, 48.0% remission, and 36.0% steroid-free remission. The durability of clinical response, remission, and steroid-free remission (W14–W54) were 68.9%, 62.9%, and 57.1%, respectively. By W54, a significant reduction in the PROs, such as the total CDAI score ( p < 0.001), stool frequency ( p < 0.001), abdominal pain score ( p < 0.001), IBDQ ( p < 0.001), IBD-F ( p < 0.05), and fatigue impact on daily activities ( p < 0.001), was observed. During VDZ treatment, arthralgia (23.7%–8.7%) and anemia (22.6%–15.9%) decreased between baseline and W54. Non-serious adverse events (SAEs; 12.2%), SAEs (7.1%), and VDZ-related rash (1.0%) were reported. Mean CD-related hospitalization duration decreased from baseline (10.2 days) to the end of the study (5.3 days).Conclusion: POLONEZ II demonstrated long-term real-world benefits of VDZ toward effectiveness, safety, and improved PROs and patients’ quality of life.Trial registration: ENCePP (EUPAS32716).

12 March 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SDSzymon Drygała
Szymon Drygała
MŻMałgorzata Żendzian-Piotrowska
Małgorzata Żendzian-Piotrowska
Michał RadzikowskiMichał Radzikowski
Michał Radzikowski
AZAnna Zalewska
Anna Zalewska
Mateusz MaciejczykMateusz Maciejczyk
Mateusz Maciejczyk
Glycation is defined as a non-enzymatic reaction wherein reducing sugars interact with amino acid residues present in proteins, resulting in the formation of advanced glycation end-products (AGE). This biochemical phenomenon is linked to several pathological conditions, particularly cardiovascular disease (CVD) and diabetes, as it significantly contributes to the onset of endothelial dysfunction and inflammation. Given these connections, vasodilatory β-blockers (VBB) have garnered interest due to their multifaceted pharmacological effects that extend beyond traditional β-adrenergic blockade. These agents not only enhance endothelial function but also exhibit notable antioxidant and anti-inflammatory properties, which may be associated with their capacity to inhibit glycation processes. In our study, we examined these properties through an in vitro and in silico study utilizing bovine serum albumin (BSA) as a model with multiple carbohydrates and aldehydes as glycation agents. Furthermore, we evaluated the binding affinity of VBB to BSA and pro-inflammatory proteins via molecular docking. The results indicated that while VBB were effective in diminishing the rates of protein glycation their effectiveness was generally lower than that of aminoguanidine, a recognized anti-glycation agent. In contrast, molecular docking analyses suggested that the anti-inflammatory properties of VBB may be due to their competition with glycation agents for binding sites on BSA, as well as their interactions with proteins integral to the activation of pro-inflammatory signaling pathways.

16 February 2024 in Immunotherapy
Verified
Journal Article
Open access
MMMonika Mach-Tomalska
Monika Mach-Tomalska
APAnna Pituch-Noworolska
Anna Pituch-Noworolska
EBEwa Bien
Ewa Bien
MMMagdalena Malanowska
Magdalena Malanowska
EMEdyta Machura
Edyta Machura
EHEdyta Heropolitańska-Pliszka
Edyta Heropolitańska-Pliszka
Aim: This retrospective study investigated real-world hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) treatment patterns in pediatric patients with primary immunodeficiency diseases (... Plain language summary Antibodies, also known as immunoglobulins, are proteins that are made by the immune system to help fight infections. In primary immunodeficiency diseases (PIDs), part of the ... Tweetable abstract Real-world Polish data on hyaluronidase-facilitated subcutaneous immunoglobulin use in pediatrics with primary immunodeficiency diseases support the feasibility of infusion every...